Business Wire

Australian Department of Home Affairs’ New Biometric System Goes Live Using Unisys Stealth(identity)™ and IDEMIA Biometrics

3.6.2020 13:48:00 EEST | Business Wire | Press release

Share

Unisys Corporation (NYSE: UIS) and IDEMIA today announced that the Australian Department of Home Affairs’ new Enterprise Biometric Identification Services (EBIS) system has gone live. EBIS is based on the Unisys Stealth(identity)™ multi-factor identity management and authentication solution and, using IDEMIA’s facial and fingerprint recognition algorithms, is one of the world’s most accurate biometric identity management systems used for visa and border processing to secure Australia’s’ borders and facilitate the flow of legitimate travellers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005403/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

EBIS will be used by the department to match the facial images and fingerprints of people including those wishing to travel to Australia such as visa applicants and the facial images for citizenship applicants. The system simultaneously facilitates the processing of legitimate travellers and is designed to support anticipated growth in visa applications, border clearances and applications for citizenship over the next 10 years.

In 2019 there was a record annual 9.5 million visitors to Australia, 3.9 million more than 10 years earlier and 220 300 more than the previous year1. To facilitate travellers’ journeys, border clearance staff need to efficiently verify the identities of travellers and confirm they are who they say they are to prevent delays, avoid queues and improve the overall experience for travellers. In the future, EBIS will provide the capability to quickly flag people who may be crossing the border with fraudulent identities.

Unisys designed and implemented the system within 18 months of signing the contract with the department. EBIS is based on the Stealth(identity) multi-factor identity management and authentication solution, which supports face, finger, iris and voice recognition. It is a robust solution designed for high-volume (more than 100,000 transactions daily) and large-scale galleries (more than 100 million records). Stealth(identity) provides the core biometric identity management functionality of EBIS including the user interface, workflows, business rules, identity data and record linking and auditing functionality. EBIS replaces the previous biometrics matching system that was also provided and supported by Unisys for the last 12 years.

Rick Mayhew, vice president and general manager, Unisys Asia Pacific said: “The long term growth in the volume of travellers that will hopefully return after COVID-19, as well as the increased risk of potential terrorist or fraudulent activity, means that effective border security is more important than ever. EBIS provides Home Affairs with greater confidence in verifying an individual’s identity for efficient and early detection of criminals and persons of national security concern who change names and obtain passports using false identities. We have worked closely with the department and our partner IDEMIA, the global leader in Augmented Identity, to deliver one of the world’s leading solutions to help protect Australia’s borders and national assets.”

The core of EBIS’ fingerprint and facial biometric matching solution uses industry-leading biometric matching algorithms from IDEMIA to quickly and accurately match fingerprints and facial images.

IDEMIA’s flagship product Multi Biometric Search Services (MBSS) is a multi-biometric engine that uses face and fingerprint matching algorithms. This product combines high scalability (over 1 billion identities possible) with high availability, which is necessary for mission-critical systems, integrated within IDEMIA’s world-leading biometric algorithms. The product can also include other modalities such as iris recognition, where required.

Tim Ferris, President of IDEMIA Asia Pacific and Senior Vice President for Public Security and Identity, added: “We are thrilled to provide the biometric engine that powers the EBIS solution. This is the continuation of years of IDEMIA’s engagement in the Australian Borders ecosystem. The combined strengths of IDEMIA behind Unisys provide the Department of Home Affairs with a flagship platform to secure the border now and into the future.”

Unisys has extensive experience supporting government departments and agencies in Australia and around the world. More than 240 government agencies worldwide use Unisys solutions. For more information on Unisys' Public Sector solutions, visit http://www.unisys.com.au/industries/government/public-sector.

1 – Australian Bureau of Statistics -
https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3401.0Main%20Features13Mar%202020

About Unisys
Unisys is a global information technology company that builds high-performance, security-centric solutions for the most demanding businesses and governments. Unisys offerings include security software and services; digital transformation and workplace services; industry applications and services; and innovative software operating environments for high-intensity enterprise computing. For more information on how Unisys builds better outcomes securely for its clients across the Government, Financial Services and Commercial markets, visit www.unisys.com.au. Follow Unisys on Twitter and LinkedIn.

###

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Nowland, The Impact Agency
+61 2 9519 5411 or +61 0413 942 179, emily@impactagency.com.au

Claire Hosegood, Unisys Asia Pacific
+61 411 253 663, claire.hosegood@au.unisys.com

Press

PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30
idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye